---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-092680"
form_type: "8-K"
ticker: "APUS"
cik: "0001894525"
company_name: "Apimeds Pharmaceuticals US, Inc."
filed_at: "2026-08-21T21:12:40+00:00"
generated_at: "2026-08-21T21:14:09.557713+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Apimeds acquires Apitox rights from FreeT: Korean clinic market, 25% US royalty

## Summary
- On Aug 19, 2026, Apimeds entered an Assignment Agreement with FreeT Inc. (successor to CNP Roen/Inscobee).
- Assigned rights include 100% of Apitox Korean medicine-clinic market rights and 25% royalty on US Apitox economic proceeds.
- Also granted 25% revenue participation on net proceeds from overseas rights deals plus quarterly clinical and commercialization updates.
- Company assumes no pre-effective-date liabilities; rights exclude global rights not held by FreeT and underlying Apitox IP.
- FreeT will support continued development and expansion and pursue future grants of non-US Apitox territories to Apimeds.

## SEC filing metadata
- accession: 0001213900-26-092680
- form_type: 8-K
- ticker: APUS
- cik: 0001894525
- company_name: Apimeds Pharmaceuticals US, Inc.
- filed_at: 2026-08-21T21:12:40+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894525/000121390026092680/0001213900-26-092680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894525/000121390026092680/ea0303076-8k_apimeds.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-092680
- JSON: https://secwatch.observer/filing/0001213900-26-092680.json
- Plain text: https://secwatch.observer/filing/0001213900-26-092680.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.